These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 10864134)

  • 1. Nimesulide: some pharmaceutical and pharmacological aspects--an update.
    Singla AK; Chawla M; Singh A
    J Pharm Pharmacol; 2000 May; 52(5):467-86. PubMed ID: 10864134
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro and in vivo pharmacological evidence of selective cyclooxygenase-2 inhibition by nimesulide: an overview.
    Famaey JP
    Inflamm Res; 1997 Nov; 46(11):437-46. PubMed ID: 9427063
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of acute low back pain with the COX-2-selective anti-inflammatory drug nimesulide: results of a randomized, double-blind comparative trial versus ibuprofen.
    Pohjolainen T; Jekunen A; Autio L; Vuorela H
    Spine (Phila Pa 1976); 2000 Jun; 25(12):1579-85. PubMed ID: 10851109
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Nimesulide (Aulin)--the selective COX-2 inhibitor in the treatment of ENT diseases].
    Arcimowicz M; Samoliński B; Gotlib T; Nyckowska J
    Otolaryngol Pol; 2002; 56(4):501-7. PubMed ID: 12378813
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nimesulide: an NSAID that preferentially inhibits COX-2, and has various unique pharmacological activities.
    Bennett A; Villa G
    Expert Opin Pharmacother; 2000 Jan; 1(2):277-86. PubMed ID: 11249549
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nimesulide is a selective COX-2 inhibitory, atypical non-steroidal anti-inflammatory drug.
    Suleyman H; Cadirci E; Albayrak A; Halici Z
    Curr Med Chem; 2008; 15(3):278-83. PubMed ID: 18333314
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical pharmacokinetics and pharmacodynamics of celecoxib: a selective cyclo-oxygenase-2 inhibitor.
    Davies NM; McLachlan AJ; Day RO; Williams KM
    Clin Pharmacokinet; 2000 Mar; 38(3):225-42. PubMed ID: 10749518
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The relatively selective cyclooxygenase-2 inhibitor nimesulide: What's going on?
    Caiazzo E; Ialenti A; Cicala C
    Eur J Pharmacol; 2019 Apr; 848():105-111. PubMed ID: 30689999
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interaction between NSAIDs and steroid in rat stomach: safety of nimesulide as a preferential COX-2 inhibitor in the stomach.
    Kataoka H; Horie Y; Koyama R; Nakatsugi S; Furukawa M
    Dig Dis Sci; 2000 Jul; 45(7):1366-75. PubMed ID: 10961716
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Selective cyclooxygenase-2 (COX-2) inhibitors: importance and limitations].
    Pairet M; Netter P
    Therapie; 1999; 54(4):433-45. PubMed ID: 10667110
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The in vivo assessment of nimesulide cyclooxygenase-2 selectivity.
    Shah AA; Murray FE; Fitzgerald DJ
    Rheumatology (Oxford); 1999 May; 38 Suppl 1():19-23. PubMed ID: 10369402
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The future of NSAID therapy: selective COX-2 inhibitors.
    Vane JR; Botting RM
    Int J Clin Pract; 2000; 54(1):7-9. PubMed ID: 10750251
    [No Abstract]   [Full Text] [Related]  

  • 13. Gastrointestinal toxicity of non-steroidal anti-inflammatory drugs: the effect of nimesulide compared with naproxen on the human gastrointestinal tract.
    Bjarnason I; Thjodleifsson B
    Rheumatology (Oxford); 1999 May; 38 Suppl 1():24-32. PubMed ID: 10369403
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Case report: reversible acute renal failure following therapy with both ketorolac (non-selective non-steroidal anti-inflammatory drug NSAID) and celecoxib (COX-2 selective) in the same patient].
    Galli G; Panzetta G
    G Ital Nefrol; 2002; 19(2):199-203. PubMed ID: 12195419
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rofecoxib: an update on physicochemical, pharmaceutical, pharmacodynamic and pharmacokinetic aspects.
    Ahuja N; Singh A; Singh B
    J Pharm Pharmacol; 2003 Jul; 55(7):859-94. PubMed ID: 12906745
    [TBL] [Abstract][Full Text] [Related]  

  • 16. COX-2-Selective NSAIDs: new and improved?
    Lichtenstein DR; Wolfe MM
    JAMA; 2000 Sep; 284(10):1297-9. PubMed ID: 10980759
    [No Abstract]   [Full Text] [Related]  

  • 17. Relationship of nimesulide safety to its pharmacokinetics: assessment of adverse reactions.
    Rainsford KD
    Rheumatology (Oxford); 1999 May; 38 Suppl 1():4-10. PubMed ID: 10369399
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetic profile and in vitro selective cyclooxygenase-2 inhibition by nimesulide in the dog.
    Toutain PL; Cester CC; Haak T; Metge S
    J Vet Pharmacol Ther; 2001 Feb; 24(1):35-42. PubMed ID: 11348485
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nimesulide. An update of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy.
    Davis R; Brogden RN
    Drugs; 1994 Sep; 48(3):431-54. PubMed ID: 7527762
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Suppression of intestinal polyp development by nimesulide, a selective cyclooxygenase-2 inhibitor, in Min mice.
    Nakatsugi S; Fukutake M; Takahashi M; Fukuda K; Isoi T; Taniguchi Y; Sugimura T; Wakabayashi K
    Jpn J Cancer Res; 1997 Dec; 88(12):1117-20. PubMed ID: 9473726
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.